Peptide Initiative

Peptides · Peptide comparison

Bestatin (Ubenimex) vs Thymosin Alpha-1

Natural dipeptide analogue aminopeptidase inhibitor with dual immunostimulatory and antitumor activity, approved in Japan as adjuvant cancer therapy

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeBestatin (Ubenimex)30–30 mgThymosin Alpha-11.6–1.6 mg
FrequencyBestatin (Ubenimex)Once dailyThymosin Alpha-1Twice weekly
AdministrationBestatin (Ubenimex)Oral (capsule)Thymosin Alpha-1Subcutaneous injection
Cycle lengthBestatin (Ubenimex)12+ weeksThymosin Alpha-18-12 weeks
Onset speedBestatin (Ubenimex)Moderate (1-2 weeks)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelBestatin (Ubenimex)Moderate human trials (Phase 1-2)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Immune

Bestatin (Ubenimex)90%
Thymosin Alpha-1No recorded rating

Healing & Recovery

Bestatin (Ubenimex)70%
Thymosin Alpha-1No recorded rating

Anti-Aging

Bestatin (Ubenimex)40%
Thymosin Alpha-1No recorded rating

Immune Activation

Bestatin (Ubenimex)No recorded rating
Thymosin Alpha-195%

Infection Fighting

Bestatin (Ubenimex)No recorded rating
Thymosin Alpha-192%

Immune Balance

Bestatin (Ubenimex)No recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Bestatin (Ubenimex)

Molecular formula
C16H24N2O4
Molecular weight
308.37 g/mol
Half-life
Approximately 2-3 hours (oral administration)
Bioavailability
Well absorbed orally; peak plasma concentration reached within 1-2 hours
CAS number
58970-76-6

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Bestatin (Ubenimex)

Oral

  • 30 mgOnce daily · Long-term, alongside maintenance chemotherapy30 mg by mouth once daily is the approved Japanese dose used as add-on therapy after leukemia remission. It helped patients, especially older adults, stay in remission longer [4][1].

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Bestatin (Ubenimex)

Adjunctive AML Immunotherapy
Bestatin is specifically approved in Japan for patients with acute non-lymphocytic leukemia who have achieved complete remission after induction chemotherapy. [10] Clinical trials demonstrated significant prolongation of disease-free survival when bestatin was added to standard maintenance therapy [3][4].
Post-Chemotherapy Immune Recovery
By stimulating bone marrow stem cell proliferation and enhancing T-lymphocyte and macrophage function, bestatin supports immune system recovery in patients whose immune function has been suppressed by cytotoxic chemotherapy [1][3].
Pulmonary Arterial Hypertension (Investigational)
Through inhibition of LTA4 hydrolase and reduction of pro-inflammatory leukotriene B4, [5] bestatin is being investigated as a novel approach to PAH. Eiger BioPharmaceuticals conducted Phase 2 trials (NCT02664558) [7] and received FDA orphan drug designation for this indication [9].
Lymphedema Management (Investigational)
The anti-inflammatory properties of bestatin via LTB4 pathway inhibition have led to Phase 2 investigation (NCT02700529) [8] for lymphedema, a condition with limited treatment options where inflammation plays a key role in disease progression.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Bestatin (Ubenimex)

Common

  • Gastrointestinal discomfort
  • Skin rash or pruritus
  • Facial flushing
  • Fatigue

Uncommon

  • Elevated liver enzymes
  • Mild leukopenia

Serious

  • Severe allergic reaction

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Bestatin (Ubenimex)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Bestatin (ubenimex) has an established safety profile based on decades of clinical use in Japan for AML maintenance therapy at 30 mg daily. [3][10] The compound is generally well-tolerated, with the most common side effects being mild gastrointestinal symptoms and skin reactions. [10] Japanese post-marketing surveillance and long-term clinical studies have not identified major safety concerns at standard doses. Phase 2 trials in the US for PAH and lymphedema [7][8] also demonstrated acceptable safety profiles at higher doses.

Contraindications

  • Known hypersensitivity to bestatin or any component of the formulation
  • Pregnancy and breastfeeding (insufficient safety data)
  • Severe hepatic impairment
  • Active autoimmune diseases in flare

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Bestatin (Ubenimex)

Choose Bestatin (Ubenimex) if…

  • Adjunctive immunotherapy following chemotherapy for acute leukemia
  • Restoring immune function during and after cancer treatment
  • Supporting bone marrow recovery post-chemotherapy
  • Emerging treatment for pulmonary arterial hypertension (PAH)

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support